肌生成抑制素及其信号转导

肌生成抑制素(myostatin),也称生长分化因子-8(growth differentiation factor-8,GDF-8),属转化生长因子B(transforming growth factor β,TGF-β)超家族的一员,是骨骼肌生长发育的负调控因子.本文介绍了myostatin的发现及保守性、myostatin的结构特征及加工成熟,重点综述了myostatin的生物学功能及其信号转导的最新研究进展.     

人转化生长因子β1在大肠杆菌胞内表达的研究

转化生长因子β(transforming growth factor β,TGFβ)是细胞增殖、分化的重要调节蛋白之一,同时还参与了细胞外基质形成、胚胎发育、骨重建等多项病理和生理过程,并在创伤愈合、免疫抑制、肿瘤抑制等多方面具有广阔的     

人转化生长因子β1成熟肽基因的克隆及序列测定

转化生长因子β1(transforming growth factor β1,TGF β1)作为细胞主要的负调控生长因子,参与了哺乳动物各种细胞的病理和生理过程。此外,TGF β1可望应用于创伤愈合、免疫抑制、肿瘤抑制等方面,具有潜在的临床应用前景。我们在完成了人TGF β1基因的克隆及其在真核细胞中的表达后,准备进行其在大肠杆菌中的高效表达研究。     

肌生成抑制素及其信号转导

肌生成抑制素（myostatin）,也称生长分化因子-8（growth differentiation factor-8,GDF-8）,属转化生长因子β（transforming growth factor β,TGF-β）超家族的一员,是骨骼肌生长发育的负调控因子。本文介绍了myostatin的发现及保守性、myostatin的结构特征及加工成熟,重点综述了myostatin的生物学功能及其信号转导的最新研究进展。     

GFRAL,新发现的GDF-15受体

<正>生长分化因子-15(growth/differentiation factor 15,GDF-15)是转化生长因子-β(transforming growth factor beta,TGF-β)超家族成员,亦称为巨噬细胞抑制因子-1(macrophage inhibitory cytokine-1,MIC-1)。GDF-15有丰富的生物多效性,参与多种疾病进程:其在心肌梗死期,可抑制心肌细胞凋亡,保护心肌;在动脉粥样硬化晚期,能抑制斑块增大;在肿瘤发生过程中,GDF-15水平升高,发挥抗炎和抗细胞凋亡作用;此外,GDF-15还参与代谢过程,并表现出优化代谢的效应,如减少摄食量、降低肥胖、     

编辑MSTN半胱氨酸节基元促进两广小花猪肌肉生长

肌生长抑制素(myostatin,MSTN)是转化生长因子 β(transforming growth factor-β,TGF-β)家族成员之一,是一种肌肉生长抑制因子.解除MSTN的生长抑制功能是提高畜禽肌肉产量的一种有效途径.TGF-β 的半胱氨酸节结构基元(cystine knot motif)能够稳定MSTN...     

GDF15在气道慢性炎症性疾病中的研究进展

气道慢性炎症性疾病是指炎症累及上和(或)下气道的慢性疾病。近年来,由于环境变化和社会经济发展,流行病学显示气道慢性炎症性疾病的患病人数不断上升,严重影响患者的生活质量和期望寿命。生长分化因子15(growth differentiation factor 15,GDF15)是一种应激反应性细胞因子,属于转录生长因子-β超家族。越来越多的研究发现,GDF15水平与气道炎症程度密切相关,并影响气道黏液高分泌,与气道慢性炎症性疾病的发生、进展及预后密切相关,是具有潜力的血清检测标志物。本文主要阐述GDF15的活化机制及其与炎症的关系,以慢性鼻-鼻窦炎、慢性阻塞性肺疾病、支气管哮喘等常见疾病为例,总结了GDF15在气道慢性炎症性疾病发生发展过程中的表达水平变化,以及对疾病生理病理过程和病情转归预后的影响,以期为临床气道慢性炎症性疾病的诊断和治疗提供理论依据和参考。     

生长分化因子-15在肥胖、糖尿病及心血管疾病中的作用

生长分化因子-15(growth differentiation factor-15,GDF-15),又称巨噬细胞抑制因子-1,是转化生长因子-β(transforming growth factor-β,TGF-β)家族的一个应激反应细胞因子,在产前发育、炎症、应激反应以及急性损伤后的组织修复中起关键作用.GDF-1...     

TGF-β诱导CTGF表达的信号转导途径及与纤维化形成

转化生长因子-β(transforming growth factor-β,TGF-β)是一种具有多重生物学效应的细胞因子,参与了多种组织器官纤维化的形成。结缔组织生长因子(connective tissue growth factor,CTGF)是一种富含半胱氨酸的多肽,是介导TGF-β致纤维化作用的重要下游因子之一。TGF-β可通过多种信号途径诱导CTGF表达,本文就这一领域的研究进展及与纤维化形成的关系做一简要综述。     

人骨肉瘤OS-732细胞系诱导血管生成作用及相关因子表达的研究

应用鸡胚绒毛尿囊膜模型（chick embryo chorioallantoic membrane,CAM),观察人骨肉瘤OS-732细胞系诱导血管生成过程及血管生长相关因子的表达。结果显示,本细胞系具有较强的促血管生成能力并表达血管内皮生长因子（vacular endothelial growth factor,VEGF),碱性成纤维细胞生长因子（basic fibroblast growth factor,bFGF0,鸡胚绒毛尿囊膜OS-732细胞系接种瘤细胞中血管内皮生长因子（VEGF）,转化生长因子β1(Transforming growth factor,TGF-β1）均呈阳性表达,而且VEGF呈持续高表达,结果表明VEGF,bFGF、TGF-β1可能共同参与骨肉瘤OS-732细胞系诱导的血管生成,而VEGF可能起着主要作用,提示阻断VEGF的作用可能影响骨肉瘤OS-732细胞系诱导的血管生成,此研究为以VEGF为靶点进行抗血管生成实验提供了依据。     

Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity,cancer, and cachexia

Growth differentiation factor 15 or macrophage inhibitory cytokine-1 (GDF15/MIC-1) is a divergent member of the transforming growth factor β superfamily and has a diverse pathophysiological roles in cancers, cardiometabolic disorders, and other diseases. GDF15 controls hematopoietic growth, energy homeostasis, adipose tissue metabolism, body growth, bone remodeling, and response to stress signals. The role of GDF15 in cancer development and progression is complicated and depends on the specific cancer type, stage, and tumor microenvironment. Recently, research on GDF15 and GDF15-associated signaling has accelerated due to the identification of the GDF15 receptor: glial cell line-derived neurotrophic factor (GDNF) family receptor α-like (GFRAL). Therapeutic interventions to target GDF15 and/or GFRAL revealed the mechanisms that drive its activity and might improve overall outcomes of patients with metabolic disorders and cancer. This review highlights the structure and functions of GDF15 and its receptor, emphasizing the pleiotropic role of GDF15 in obesity, tumorigenesis, metastasis, immunomodulation, and cachexia.     

Functional roles of GDF15 in modulating microenvironment to promote carcinogenesis

Obesity and related metabolic dysregulation are risk factors for many types of cancer. The interactions between a developing tumor and its microenvironment are known to implicate a complex “crosstalk” among the factors produced by the population of cells. Among these factors, Growth and differentiation factor 15 (GDF15) has a functional role in cancer. GDF15 expression is induced in response to the conditions associated with cellular stress and diseases. The GDF15 receptor, a member of the glial-cell-derived neurotropic factor family (GDNF), is a GDNF family receptor α-like (GFRAL) protein. GDF15 induces pro-angiogenic effects in tumors. However, GDF15 could affect tumorigenesis both positively and negatively. With a better understanding of the upstream disease pathways reflected by GDF15, new treatment targets may emerge.     

Growth differentiation factor‐15 (GDF‐15) suppresses in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2)

Growth differentiation factor‐15 (GDF‐15) and the CCN family member, connective tissue growth factor (CCN2), are associated with cardiac disease, inflammation, and cancer. The precise role and signaling mechanism for these factors in normal and diseased tissues remains elusive. Here we demonstrate an interaction between GDF‐15 and CCN2 using yeast two‐hybrid assays and have mapped the domain of interaction to the von Willebrand factor type C domain of CCN2. Biochemical pull down assays using secreted GDF‐15 and His‐tagged CCN2 produced in PC‐3 prostate cancer cells confirmed a direct interaction between these proteins. To investigate the functional consequences of this interaction, in vitro angiogenesis assays were performed. We demonstrate that GDF‐15 blocks CCN2‐mediated tube formation in human umbilical vein endothelial (HUVEC) cells. To examine the molecular mechanism whereby GDF‐15 inhibits CCN2‐mediated angiogenesis, activation of α_Vβ₃ integrins and focal adhesion kinase (FAK) was examined. CCN2‐mediated FAK activation was inhibited by GDF‐15 and was accompanied by a decrease in α_Vβ₃ integrin clustering in HUVEC cells. These results demonstrate, for the first time, a novel signaling pathway for GDF‐15 through interaction with the matricellular signaling molecule CCN2. Furthermore, antagonism of CCN2 mediated angiogenesis by GDF‐15 may provide insight into the functional role of GDF‐15 in disease states. J. Cell. Biochem. 114: 1424–1433, 2013. © 2012 Wiley Periodicals, Inc.     

Camptothecin effectively treats obesity in mice through GDF15 induction

Elevated circulating levels of growth differentiation factor 15 (GDF15) have been shown to reduce food intake and lower body weight through activation of hindbrain receptor glial-derived neurotrophic factor (GDNF) receptor alpha-like (GFRAL) in rodents and nonhuman primates, thus endogenous induction of this peptide holds promise for obesity treatment. Here, through in silico drug-screening methods, we found that small molecule Camptothecin (CPT), a previously identified drug with potential antitumor activity, is a GDF15 inducer. Oral CPT administration increases circulating GDF15 levels in diet-induced obese (DIO) mice and genetic ob/ob mice, with elevated Gdf15 expression predominantly in the liver through activation of integrated stress response. In line with GDF15’s anorectic effect, CPT suppresses food intake, thereby reducing body weight, blood glucose, and hepatic fat content in obese mice. Conversely, CPT loses these beneficial effects when Gdf15 is inhibited by a neutralizing antibody or AAV8-mediated liver-specific knockdown. Similarly, CPT failed to reduce food intake and body weight in GDF15’s specific receptor GFRAL-deficient mice despite high levels of GDF15. Together, these results indicate that CPT is a promising anti-obesity agent through activation of GDF15-GFRAL pathway.

Elevated circulating levels of growth differentiation factor 15 (GDF15) have been shown to reduce food intake and lower body weight in rodents and nonhuman primates. This study reveals that the small molecule Camptothecin induces endogenous GDF15, suppressing food intake and reducing body weight in obese mice, suggesting a promising candidate for anti-obesity treatment.     

Overview of growth differentiation factor 15 in metabolic syndrome

Growth and differentiation factor 15 (GDF15) is a member of the transforming growth factor-β (TGF-β) superfamily. GDF15 has been linked with several metabolic syndrome pathologies such as obesity and cardiovascular diseases. GDF15 is considered to be a metabolic regulator, although its precise mechanisms of action remain to be determined. Glial cell-derived neurotrophic factor family receptor alpha-like (GRAL), located in the hindbrain, has been identified as the receptor for GDF15 and signals through the coreceptor receptor tyrosine kinase (RET). Administration of GDF15 analogues in preclinical studies using various animal models has consistently been shown to induce weight loss through a reduction in food intake. GDF15, therefore, represents an attractive target to combat the current global obesity epidemic. In this article, we review current knowledge on GDF15 and its involvement in metabolic syndrome.     

GDF-15 promotes mitochondrial function and proliferation in neuronal HT22 cells

The neuronal cell line HT22 is an excellent model for studying Parkinson's disease. Growth differentiation factor 15 (GDF15) plays a critical role in Parkinson's disease, but the molecular mechanism involved are not well understood. We constructed the GDF15 overexpression HT22 cells and detected the effects of overexpression of GDF15 on the viability, oxygen consumption, mitochondrial membrane potential of oligomycin-treated HT22 cells. In addition, we used a high-throughput RNA-sequencing to study the lncRNA and mRNA expression profiling and obtained key lncRNAs, mRNA, gene ontology (GO), and Kyoto encyclopedia of genes and genomes (KEGG) pathway. The expression of selected DElncRNAs was validated by quantitative real-time PCR (qRT-PCR). Our results showed that overexpression of GDF15 significantly reversed the cells viability, oxygen consumption, and mitochondrial membrane potential effect caused by oligomycin in HT22 cells. The 1093 DEmRNAs and 395 DElncRNAs in HT22 cells between GDF15-oligomycin non-intervention group and a normal control-oligomycin un-intervention group were obtained, and 394 DEmRNAs and 271 DElncRNAs in HT22 cells between GDF15-oligomycin intervention group and normal control-oligomycin intervention group were identified. Base on the GO and KEGG enrichment analysis of between GDF15-oligomycin intervention group and normal control-oligomycin intervention group, positive regulation of cell proliferation was most significantly enriched GO terms, and Cav1 was enriched in positive regulation of cell proliferation pathway. PI3K-Akt signaling pathway was one significantly enriched pathway in GDF15-oligomycin intervention group. The qRT-PCR results were consistent with RNA-sequencing, generally. GDF15 might promote mitochondrial function and proliferation of HT22 cells by regulating PI3K/Akt signaling pathway. Our study may be helpful in understanding the potential molecular mechanism of GDF15 in Parkinson's disease.     

Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells

Targeting dysregulated signaling pathways in tumors has led to the development of a novel class of signal transduction inhibitors, including inhibitors of the epidermal growth factor (EGF) receptor (EGFR). To dissect oncogenic pathways, identify key pathway determinants, and evaluate the efficacy of targeted agents, it is vital to develop technologies that allow the detection of temporal signaling events under physiological conditions. Here we report the application of a label-free optical biosensor to reveal the rapid response of cancer cells to EGF, expressed as a dynamic mass redistribution (DMR) signal. In response to EGF, squamous cell carcinoma of the head and neck cells exhibited a rapid rise in DMR signal, whereas lung adenocarcinoma cells showed a biphasic DMR profile, suggesting a cell type-dependent DMR response. Pharmacological studies suggested the importance of EGFR and the phosphatidylinositol-3 kinase pathway in mediating the EGF-induced DMR response. The defined DMR signatures offer a simple yet sensitive tool for evaluating EGFR-targeted agents, as shown with gefitinib and erlotinib. The assay can also be used for cell-based high-throughput screening of EGF pathway inhibitors, as demonstrated by its robust performance in a 384-well plate format (Z′?>?0.5). This technology is applicable to other oncogenic pathways for the discovery of novel therapeutic agents for the treatment of various cancers.     

TGF-β对肿瘤微环境中免疫监视及细胞外基质的调控作用

转化生长因子β(transforming growth factorβ,TGF-β)是一种多功能的细胞因子,能够调控细胞增殖、分化、黏附、迁移及凋亡等行为,在胚胎发育过程和成体组织稳态维持中发挥重要的作用。而在许多疾病状态下,特别是在癌症中,TGF-β不仅能够影响肿瘤细胞的增殖与转移,其对于肿瘤微环境的调控与塑造也受到越来越多的关注。肿瘤微环境是指肿瘤在发生和发展过程中所处的内环境,由肿瘤细胞本身、相邻正常组织中的间质细胞,以及这些细胞所释放的众多细胞因子等共同组成。肿瘤微环境是肿瘤发展的重要机制,也是肿瘤临床治疗领域亟待探索的关键问题。TGF-β是调节肿瘤微环境组成和功能的主要参与者之一。在本综述中,将着重讨论TGF-β对于肿瘤微环境中的免疫监视机制及肿瘤细胞外基质的主要影响。即TGF-β对于构成先天性和获得性抗肿瘤免疫应答的各种类群的免疫细胞具有广泛的调控作用,从而削弱宿主的肿瘤免疫监视功能。同时,TGF-β通过促进肿瘤相关成纤维细胞的产生,以及肿瘤细胞外基质的纤维化,有助于肿瘤的恶变和转移。此外,还介绍了通过阻断肿瘤微环境中TGF-β信号通路进行肿瘤治疗的主要策略及独特优势。而未来进一步解析TGF-β信号在肿瘤微环境中的复杂调控作用,并建立有效的靶向干预方法对于开发高效的抗肿瘤药物具有重要的意义。     

Extracellular‐signal‐regulated kinase/mitogen‐activated protein kinase signaling as a target for cancer therapy: an updated review

Mitogen‐activated protein kinase (MAPK) signaling pathway is activated in a wide spectrum of human tumors, exhibiting cardinal oncogenic roles and sustained inhibition of this pathway is considered as a primary goal in clinic. Within this pathway, receptor tyrosine kinases such as epithelial growth factor receptor, mesenchymal–epithelial transition, and AXL act as upstream regulators of RAS/RAF/MEK/extracellular‐signal‐regulated kinase. MAPK signaling is active in both early and advanced stages of tumorigenesis, and it promotes tumor proliferation, survival, and metastasis. MAPK regulatory effects on cellular constituent of the tumor microenvironment is for immunosuppressive purposes. Cross‐talking between MAPK with oncogenic signaling pathways including WNT, cyclooxygenase‐2, transforming growth factor‐β, NOTCH and (in particular) with phosphatidylinositol 3‐kinase is contributed to the multiplication of tumor progression and drug resistance. Developing resistance (intrinsic or acquired) to MAPK‐targeted therapy also occurs due to heterogeneity of tumors along with mutations and negative feedback loop of interactions exist between various kinases causing rebound activation of this signaling. Multidrug regimen is a preferred therapeutic avenue for targeting MAPK signaling. To enhance patient tolerance and to mitigate potential adversarial effects related to the combination therapy, determination of a desired dose and drug along with pre‐evaluation of cancer‐type‐specific kinase mutation and sensitivity, especially for patients receiving triplet therapy is an urgent need.